W
Walter M. Cronin
Researcher at University of Pittsburgh
Publications - 34
Citations - 12613
Walter M. Cronin is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 22, co-authored 34 publications receiving 12155 citations. Previous affiliations of Walter M. Cronin include University of California, Los Angeles.
Papers
More filters
Journal Article
National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
TL;DR: The proposed NSA BP B-35 trial will have the same design as NSABP B-24 but will compare tamoxifen with anastrozole in postmenopausal women, and outcomes will include both ipsilateral and contralateral new breast cancer and recurrences, as well as the occurrence of regional and distant disease.
Book ChapterDOI
The Use of Tamoxifen and Raloxifene for the Prevention of Breast Cancer
D. Lawrence Wickerham,Joseph P. Costantino,Victor G. Vogel,Walter M. Cronin,Reena S. Cecchini,Leslie G. Ford,Norman Wolmark +6 more
TL;DR: The NSABP Study of Tamoxifen and Raloxifene in a population of healthy postmenopausal women at increased risk for breast cancer to determine the relative effects on the risk of invasive breast cancer.
Journal ArticleDOI
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
Eleftherios P. Mamounas,Barry C. Lembersky,Jong-Hyeon Jeong,Walter M. Cronin,Barbara Harkins,Charles E. Geyer,D L Wickerham,Soonmyung Paik,Joseph P. Costantino,Norman Wolmark +9 more
TL;DR: Aromatase Inhibitors as Adjuvant Therapy (AIT) as discussed by the authors significantly improves disease-free and overall survival in patients with stage I, II, or III breast cancer and hormone receptor-positive tumors.
Journal ArticleDOI
Contralateral Breast Cancer and Thromboembolic Events in African American Women Treated With Tamoxifen
Worta McCaskill-Stevens,John W Wilson,John Bryant,Eleftherios P. Mamounas,Lori Garvey,Joan James,Walter M. Cronin,D. Lawrence Wickerham +7 more
TL;DR: African American and white women appear to have the same risks of contralateral breast cancer and thromboembolic events in response to tamoxifen treatment.
Journal ArticleDOI
Baseline Mammographic Breast Density and the Risk of Invasive Breast Cancer in Postmenopausal Women Participating in the NSABP Study of Tamoxifen and Raloxifene (STAR)
Reena S. Cecchini,Joseph P. Costantino,Jane A. Cauley,Walter M. Cronin,D. Lawrence Wickerham,Hanna Bandos,Joel L. Weissfeld,Norman Wolmark +7 more
TL;DR: The BI-RADS breast composition classification system is a quick and readily available method for assessing breast density for risk prediction evaluations; however, its addition to the Gail model does not seem to provide substantial predictability improvements in this population of postmenopausal healthy women at increased risk for breast cancer.